Drug Trials Snapshots: JOENJA (leniolisib)

Drug Trials Snapshots: JOENJA (leniolisib) JOENJA is a kinase inhibitor that is used to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older who weigh at least 45 kg. APDS is an inherited disease that impacts the immune system. APDS often causes a decrease in T and B cells that fight infection as well as an increase in lymph node size. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-joenja